Клінічне значення експресії рецепторів андрогенів у хворих на рак молочної залози

І. Б. Щепотін; О. С. Зотов; Р. В. Любота; М. Ф. Анікусько; І. І. Любота

doi:10.24026/1818-1384.2(47).2014.75433

Автор(и)

І. Б. Щепотін Національний інститут раку, Київ, Ukraine
О. С. Зотов Національний медичний університет імені О.О. Богомольця, Київ, Ukraine
Р. В. Любота Національний медичний університет імені О.О. Богомольця, Київ, Ukraine
М. Ф. Анікусько Київський міський клінічний онкологічний центр, Київ, Ukraine
І. І. Любота Київський міський клінічний онкологічний центр, Київ, Ukraine

DOI:

https://doi.org/10.24026/1818-1384.2(47).2014.75433

Ключові слова:

breast cancer, androgen receptors, treatment

Анотація

The review discusses the importance of the expression of androgen receptor (AR) in patients with breast cancer (BC). Determination of these receptors may be the basis of choice of adequate therapy. They can be regarded as a potential therapeutic target in the treatment of patients ER-/AP + breast cancer, and anti-androgens – not only, as a new method of hormone therapy, but also as an alternative to pertuzumab in patients with ER-/HER2 + / AP + tumors, which for various reasons can not receive therapy with monoclonal antibodies.

Біографії авторів

І. Б. Щепотін, Національний інститут раку, Київ

I. Shchepotin

О. С. Зотов, Національний медичний університет імені О.О. Богомольця, Київ

А.С. Зотов

Р. В. Любота, Національний медичний університет імені О.О. Богомольця, Київ

Р.В. Любота

М. Ф. Анікусько, Київський міський клінічний онкологічний центр, Київ

М.Ф. Аникусько

І. І. Любота, Київський міський клінічний онкологічний центр, Київ

И.И. Любота

Посилання

Бюлетень Національного канцер-реєстру No 14 – "Рак в Україні, 2011-2012", Київ – 2013.

Andò S., De Amicis F., Rago V. et al. Breast cancer: from estrogen to androgen receptor // Mol. Cell. Endocrinol. – 2002. – Vol. 193, No1. – P. 121-128. https://doi.org/10.1016/s0303-7207(02)00105-3

Billar J.A., Dueck A.C., Stucky C.H. et al. Triple-negative breast cancers: unique clinical presentations and outcomes // Ann. Surg. Oncol. – 2010. – Vol. 17, Suppl. 3. – P. 384-390. https://doi.org/10.1245/s10434-010-1260-4

Birrell S.N., Butler L.M., Harris J.M. et al. Disruption of androgen receptor signalling by synthetic progestins may increase risk of developing breast cancer // FASEB J. – 2007. – Vol. 21. – P. 2285-2293. https://doi.org/10.1096/fj.06-7518com

Burger H.G. Androgen production in women // Fertil Steril. – 2002. – Vol. 77, Suppl 4. – P. 3-5. https://doi.org/10.1016/s0015-0282(02)02985-0

Castellano I., Allia E., Accortanzo V. et al. Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers // Breast Cancer Res. Treat. – 2010. – Vol. 124, No 1. – P. 607-617. https://doi.org/10.1007/s10549-010-0761-y

Cauley J.A., Lucas F.L., Kuller L.H. et al. Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer // Study of Osteoporotic Fractures Research Group // Ann. Intern. Med. – 1999. – Vol. 130, No 4. – P. 270-277. https://doi.org/10.7326/0003-4819-130-4_part_1-199902160-00004

Cops E.J., Bianco-Miotto T., Moore N.L. et al. Antiproliferative actions of the synthetic androgen, mibolerone, in breast cancer cells are mediated by both androgen and progesterone receptors // J. Steroid Biochem. Mol. Biol. – 2008. – Vol. 110, No 2. – P. 236-243. https://doi.org/10.1016/j.jsbmb.2007.10.014

Dimitrakakis C., Zhou J., Wang J. et al. A physiologic role for testosterone in limiting estrogenic stimulation of the breast // Menopause. – 2003 – Vol. 10. – P. 292-298. https://doi.org/10.1097/01.gme.0000055522.67459.89

Dunn J.F., Nisula B.C., Rodbard D. Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroidbinding globulin in human plasma // J. Clin. Endocrinol. Metab. – 1981. – Vol. 53. – P. 58-68. https://doi.org/10.1210/jcem-53-1-58

Farmer P., Bonnefoi H., Becette V. et al. Identification of molecular apocrine breast tumours by microarray analysis // Oncogene. – 2005. – Vol. 24, No 29. – P. 4660-4671. https://doi.org/10.1038/sj.onc.1208561

Fruzzetti F. Adrenal androgen secretion in PCOS // Fert. Ster. – 1995. – Vol. 63, No 4. – P. 734-741.

Gianni L., Pienkowski T., Im Y.H. et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial // Lancet Oncol. – 2011. – Vol. 13, No 4. – P. 25-32. https://doi.org/10.1016/s1470-2045(11)70336-9

Gonzale L.O., Corte M.D., Vazquez J. et al. Androgen receptor expression in breast cancer: relationship with clinicopathological characteristics of the tumors, prognosis, and expression of metalloproteases and their inhibitors // BMC Cancer. – 2008. – Vol. 8. – P. 149. https://doi.org/10.1186/1471-2407-8-149

Gonzalez-Angulo A.M., Stemke-Hale K., Palla S.L. et al. Androgen Receptor Levels and Association with PIK3CA Mutations and Prognosis in Breast Cancer // Clin. Cancer Res. – 2009. – Vol. 15, No 2. – P. 2472-2478. https://doi.org/10.1158/1078-0432.ccr-08-1763

Greeve M.A., Allan R.K., Harvey J.M., Bentel J.M. Inhibition of MCF-7 breast cancer cell proliferation by 5-dihydrotestosterone; a role for p21(Cip1/Waf1) // J. Mol. Endocrinol. – 2004. – Vol. 32, No 7. – P. 793-810. https://doi.org/10.1677/jme.0.0320793

Hickey T.E., Robinson J.L., Carroll J.S., Tilley W.D. Minireview: the androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene? // Mol. Endocrinol. – 2012. – Vol. 26, No 6. – P. 1252-1267. https://doi.org/10.1210/me.2012-1107

Hu D.G., Mackenzie P.I. Estrogen receptor, fos-related antigen-2, and c-Jun coordinately regulate human UDP glucuronosyltransferase 2B15 and 2B17 expression in response to 17-estradiol in MCF-7 cells // Mol. Pharmacol. – 2009. – Vol. 76, No 4. – P. 425-439. https://doi.org/10.1124/mol.109.057380

Hu R., Dawood S., Holmes M.D. et al. Androgen receptor expression and breast cancer survival in postmenopausal women // Clin. Cancer Res. – 2011. – Vol. 17, No 4. – P. 1867-1874. https://doi.org/10.1158/1078-0432.ccr-10-2021

Kao J., Salari K., Bocanegra M. et al. Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery // PLoS One. – 2009. – Vol. 4, No 7. – P. 6146. https://doi.org/10.1371/journal.pone.0006146

Kimura N., Mizokami A., Oonuma T. et al. Immunocytochemical localization of androgen receptor with polyclonal antibody in paraffinembedded human tissues // J. Histochem. Cytochem. – 1993. – Vol. 41, No 1. – P. 671-678. https://doi.org/10.1177/41.5.8468448

Lapointe J., Fournier A., Richard V., Labrie C. Androgens down-regulate bcl-2 protooncogene expression in ZR-75-1 human breast cancer cells // Endocrinology. – 1999. – Vol. 140. – P. 416-421. https://doi.org/10.1210/en.140.1.416

Lin L., de Mattos F., Maciel K. et al. Coordinated expression of oestrogen and androgen receptors in HER2-positive breast carcinomas: impact on proliferative activity // Journal of clinical pathology. – 2012. – Vol. 65, No 1. – P. 64-68. https://doi.org/10.1136/jclinpath-2011-200318

Longcope C. Androgen Metabolism In "Gynecology and Obstetrics" ed. by J.J. Sciarra, NY. –1993. – Vol. 5, No 2. – P. 1-13.

Macedo L.F., Guo Z., Tilghman S.L. et al. Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole // Cancer Res. – 2006 – Vol. 66, No 9. – P. 7775-7782. https://doi.org/10.1158/0008-5472.can-05-3984

Moinfar F., Okcu M., Tsybrovskyy O. et al. Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies // Cancer. – 2003. – Vol. 98. – P. 703-711. https://doi.org/10.1002/cncr.11532

Nahleh Z. Androgen receptor as a target for the treatment of hormone receptor-negative breast cancer: an unchartered territory // Future Oncol. – 2008. – Vol. 4. – P. 15-21. https://doi.org/10.2217/14796694.4.1.15

Narita D., Raica M., Suciu C. et al. Immunohistochemical expression of androgen receptor and prostate-specific antigen in breast cancer // Folia Histochem. Cytobiol. – 2006. – Vol. 44, No 4. – P. 165-172.

Niemeier L.A., Dabbs D.J., Beriwal S. et al. Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation // Mod. Pathol. – 2010. – Vol. 23, No 2. – P. 205-212. https://doi.org/10.1038/modpathol.2009.159

Ni M., Chen Y., Lim E. et al. Targeting androgen receptor in estrogen receptor-negative breast cancer // Cancer Cell. – 2011. – Vol. 14, No1. – P. 119-131. https://doi.org/10.1016/j.ccr.2011.05.026

Ortmann J., Prifti S., Bohlmann M.K. et al. Testosterone and 5-dihydrotestosterone inhibit in vitro growth of human breast cancer cell lines // Gynecol. Endocrinol. – 2002. – Vol. 16, No 2. – P. 113-120. https://doi.org/10.1080/gye.16.2.113.120

Park S., Koo J.S., Kim M.S. et al. Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers // Ann. Oncol. – 2011. – Vol. 22, No 8. – P. 1755-1762. https://doi.org/10.1093/annonc/mdq678

Park S., Koo J., Park H.S. et al. Expression of androgen receptors in primary breast cancer // Ann. Oncol. – 2010. – Vol. 21, No 3. – P. 488-492. https://doi.org/10.1093/annonc/mdp510

Perou C.M., Sorlie T., Eisen M.B. et al. Molecular portraits of human breast tumours // Nature. –2000. – Vol. 406, No 6797. – P. 747-752. https://doi.org/10.1038/35021093

Peters A.A., Buchanan G., Ricciardelli C. et al. Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer // Cancer Res. – 2009. – Vol. 69. – P. 6131-6140. https://doi.org/10.1158/0008-5472.can-09-0452

Qu Q., Mao Y., Fei X., Shen K. The Impact of Androgen Receptor Expression on Breast Cancer Survival: A Retrospective Study and Meta-Analysis // PLoS ONE. – 2013. – Vol. 8, No 12. – P. 1-8. https://doi.org/10.1371/journal.pone.0082650

Riva C., Dainese E., Caprara G. et al. Immunohistochemical study of androgen receptors in breast carcinoma. Evidence of their frequent expression in lobular carcinoma // Virchows Arch. – 2005. – Vol. 447, No 1. – P. 695-700. https://doi.org/10.1007/s00428-005-0003-6

Ruizeveld de Winter J.A., Trapman J., Vermey M. et al. Androgen receptor expression in human tissues: an immunohistochemical study // J. Histochem. Cytochem. – 1991. – Vol. 39, No 1. – P. 927-936. https://doi.org/10.1177/39.7.1865110

Schippinger W., Regitnig P., Dandachi N. et al. Evaluation of the prognostic significance of androgen receptor expression in metastatic breast cancer // Virchows Arch. – 2006. – Vol. 449. – P. 24-30. https://doi.org/10.1007/s00428-006-0213-6

Sikora M.J., Cordero K.E., Larios J.M. et al. The androgen metabolite 5-androstane-3,17-diol (3 Adiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance // Breast Cancer Res. Treat. – 2009. – Vol. 115, No 2. – P. 289-296. https://doi.org/10.1007/s10549-008-0080-8

Simpson E.R. Aromatization of androgens in women: current concepts and findings // Fertil. Steril. – 2002. – Vol. 77, Suppl 4. – P. 6-10. https://doi.org/10.1016/s0015-0282(02)02984-9

Senkus E., Kyriakides S., Penault-Llorca F., Poortmans P., Thompson A., Zackrisson S., Cardoso F. on behalf of the ESMO Guidelines Working Group. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up // Ann. Oncol. – 2013. – Vol. 24, Suppl. 6. – P. vi7-vi23. https://doi.org/10.1093/annonc/mdt284

Soiland H., Korner H., Skaland I. et al. Prognostic relevance of androgen receptor detection in operable breast cancer // J. Surg. Oncol. – 2008. – Vol. 98, No 3. – P. 551-558. https://doi.org/10.1002/jso.21156

Sorlie T., Perou C.M., Tibshirani R. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications // Proc. Natl. Acad. Sci. USA. – 2001. – Vol. 98, No 19. – P. 10869-10874. https://doi.org/10.1073/pnas.191367098

Sorlie T., Tibshirani R., Parker J. et al. Repeated observation of breast tumor subtypes in independent gene expression data sets // Proc. Natl. Acad. Sci. USA. – 2003. – Vol. 100, No 14. – P. 8418-8423. https://doi.org/10.1073/pnas.0932692100

Sotiriou C., Neo S.Y., McShane L.M. et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study // Proc. Natl. Acad. Sci. USA. – 2003. – Vol. 100, No 18. – P. 10393-10398. https://doi.org/10.1073/pnas.1732912100

Speroff L., Glass R.H., Kase N.G. Clinical Gynecologic Endocrinology and Infertility // 5th ed., Williams & Wilkins, 1994. – 842 p.

Suzuki T., Miki Y., Moriya T. et al. In situ production of sex steroids in human breast carcinoma // Med. Mol. Morphol. – 2007. – Vol. 40, No 3. – P. 121-127. https://doi.org/10.1007/s00795-007-0365-8

Takeuchi H., Tsuji K., Ueo H. et al. Clinicopathological feature and long-term prognosis of apocrine carcinoma of the breast in Japanese women // Breast Cancer Res. Treat. – 2004. – Vol. 88, No 1. – P. 49-54. https://doi.org/10.1007/s10549-004-9495-z

Tanaka K., Imoto S., Wada N. et al. Invasive apocrine carcinoma of the breast: clinicopathologic features of 57 patients // Breast J. – 2008. – Vol. 14, No 2. – P. 164-168. https://doi.org/10.1111/j.1524-4741.2007.00548.x

Zhuang Y., Saaristo R., Ylikomi T. et al. An in vitro longterm culture model for normal human mammary gland: expression and regulation of steroid receptors // Cell Tissue Res. – 2003. – Vol. 311, No 3. – P. 217-226.

Zhou J., Ng S., Adesanya-Famuiya O. et al. Testosterone inhibits estrogen-induced mammary epithelial proliferation and suppresses estrogen receptor expression // FASEB J. – 2000. – Vol. 14, No 1. – P. 1725-1730. https://doi.org/10.1096/fj.99-0863com